Pfizer stock: FDA expands Tukysa’s breast cancer approval
Pfizer’s new Tukysa FDA approval follows an 11% U.S. sales decline in Q2. What the label changes, its 0.9% revenue share and the November 3 earnings checkpoint.
Tag
#Tukysa
1 article
TECHi reporting and analysis covering Tukysa. 1 article, newest first.